On demand webinar for the Qdenga Launch Webinar. Professor Derek Evans providing an overview of the implementation and optimisation of Qdenga in practice
C-APROM/GB/QDE/0170 |
February 2025
▼ This medicinal product is subject to additional monitoring.
GB & NI: Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard.
ROI: Adverse events should be reported to the Pharmacovigilance Unit at the Health Products Regulatory Authority. Reporting forms and information can be found at: www.hpra.ie.
GB, NI and ROI: Adverse events should also be reported to Takeda UK Ltd at: AE.GBR-IRL@takeda.com